Read our latest announcements below!
Mustang Bio, Inc. and Minaris Regenerative Medicine GmbH have announced they have signed an agreement to enable technology transfer and GMP clinical manufacturing of MB-107 lentiviral gene therapy program for the treatment of X-linked severe combined immunodeficiency (“XSCID”), also known as bubble boy disease, in Europe.